DIFFERENTIAL REDUCTION IN THE VOLUME OF LEIOMYOMA AND UTERUS DURING BUSERELIN TREATMENT

被引：6

作者：

PUZIGACA, Z ^{[1
]}

PRELEVIC, GM ^{[1
]}

SRETENOVIC, Z ^{[1
]}

机构：

[1] CTR FAMILY PLANNING & HUMAN REPROD, BELGRADE, YUGOSLAVIA

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 1994年 / 8卷 / 01期

关键词：

LEIOMYOMA; GONADOTROPIN RELEASING HORMONE AGONIST; BUSERELIN;

D O I：

10.3109/09513599409028456

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Twenty-four women (mean age 42.0 +/- 2.4 years) with leiomyoma underwent treatment with a gonadotropin releasing hormone (GnRH) agonist (buserelin) for 6 months at a dose of 1200 mug daily intranasally for the first 2 months, followed by 900 mug daily for 4 months. The volume of the uterus and of individual leiomyomas were measured by echosonography before treatment, every 2 months during treatment, and every 2 months for 6 months after cessation of therapy (a total of 7 evaluations). A control group, comprising 14 women with untreated leiomyoma, underwent ultrasound scanning every 2 months for 6 months. A significant reduction in the volume of the uterus and leiomyomas was observed after the first 2 months of treatment in all but one patient. Leiomyomas showed a greater reduction in volume (54.6 +/- 2.2%) than did the uterus (41.8 +/- 2.3%; p = 0.0003). They also showed a more rapid increase in volume after cessation of therapy (p = 0.03). The control group showed an insignificant increase in the size of the uterus and individual leiomyomas over the 6 months' monitoring. The differences observed in reduction of the volumes of the leiomyomas and the uterus during the state of hypoestrogenism induced by buserelin, as well as in their regrowth after cessation of treatment, can be explained by the greater number of estrogen receptors in leiomyoma tissue and a possible lower rate of conversion of estradiol into estrone.

引用

页码：39 / 43

页数：5

共 21 条

[1] Feroze R.M., Dewhurst J., Benign tumors of the uterus, Integrated Obstetrics and Gynecology for Postgraduates, 3rd edn., pp. 696-703, (1981)
[2] Fraser H.M., Baird D.T., Clinical application of LHRH analogues, Baillière's Clin. Endocrinol. Metab., 1, pp. 43-47, (1987)
[3] Miller N.F., Ludovici P.P., Origin and development of uterine fibroids, Am. J. Obstet. Gynecol., 70, pp. 720-726, (1955)
[4] Filicori M., Hall D.A., Loughlin J.S., Rivier J., Vale W., A conservative approach to the management of uterine leiomyoma: pituitary desensitisation by an LHRH analogue, Am. J. Obstet. Gynecol., 147, pp. 726-727, (1983)
[5] Healy D., Fraser H., Lawson S., Shrinkage of a uterine fibroid after subcutaneous infusion of a LHRH agonist, Br. Med. J., 289, pp. 1267-1268, (1984)
[6] Coddington C.C., Collins R.L., Shawker T.H., Anderson R., Loriaux D.L., Winkel C.A., Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri, Fertil. Steril., 45, pp. 624-629, (1986)
[7] West C.P., Lumsden M.A., Lawson S., Williamson J., Baird D.T., Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as monthly subcutaneous depot, Fertil. Steril., 48, pp. 45-51, (1987)
[8] Perl V., Marquez J., Schally A.V., Comaru-Schally A.M., Leal G., Zacharias S., Gomez-Lira C., Treatment of leiomyomata uteri with D-Trp6-luteinizing hormone-releasing hormone, Fertil. Steril., 48, pp. 383-389, (1987)
[9] Maheux K., Lemay A., Turcot-Lemay L., Dose-related inhibition of acute luteinizing hormone-releasing hormone agonist treatment for uterine leiomyomas, Am. J. Obstet. Gynecol., 158, pp. 361-364, (1988)
[10] Nakaniura Y., Yoshimura Y., Yamada H., Ubukata Y., Ando M., Suzuki M., Treatment of uterine leiomyomata with a luteinizing hormone-releasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women, Fertil. Steril., 55, pp. 900-905, (1991)

← 1 2 3 →